Vor Biopharma reports third quarter loss and reduced R&D expenses
Vor Biopharma Inc. reported a net loss of $812.7 million for Q3 2025, a significant increase from $27.6 million in Q3 2024. Operating expenses slightly decreased to $28.1 million, with R&D expenses down to $14.1 million due to reduced stock-based compensation and headcount. Cash reserves were $170.5 million, with funding projected into Q2 2027. The company expanded its leadership and highlighted late-stage data for telitacicept.
Vor Biopharma Inc. reported a net loss of $812.7 million for the third quarter of 2025, compared to a net loss of $27.6 million for the same period in 2024. Total operating expenses were $28.1 million, slightly down from $28.5 million in the third quarter of 2024. Research and development expenses decreased to $14.1 million from $21.8 million, mainly due to lower stock-based compensation and headcount, offset by increased spending on telitacicept for generalized myasthenia gravis. Cash, cash equivalents, and marketable securities were $170.5 million as of September 30, 2025, with projected funding into the second quarter of 2027 after additional financing activities. The company highlighted late-stage data readouts for telitacicept and expanded its executive leadership and board during the quarter. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575556-en) on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
